Dulaglutide

The Dulaglutide evidence base cited here is 7 sources — 4 clinical, 1 review, 1 regulatory. Its strongest evidence is human — 4 clinical studies, most recently 2019 ("Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND)"). Regulatory status: FDA-approved (Trulicity).

• The REWIND cardiovascular outcomes trial (Lancet 2019, n=9,901, median follow-up 5.4 years) showed once-weekly dulaglutide reduced the primary MACE composite endpoint by 12% (HR 0.88, p=0.026) in T2D patients, including a notably large proportion with no prior cardiovascular disease — supporting cardioprotection even in lower-risk populations.
• The AWARD clinical development program (six Phase 3 trials) established dulaglutide 1.5 mg as superior to exenatide, insulin glargine, metformin, and sitagliptin comparators on HbA1c reduction, with AWARD-1 demonstrating -1.51% HbA1c vs -0.99% for exenatide at 52 weeks.
• As a once-weekly GLP-1 agonist fused to an IgG4 Fc fragment, dulaglutide has a half-life of ~5 days requiring only weekly subcutaneous injection; its large molecular weight minimizes renal filtration and the Fc fusion provides protection from dipeptidyl peptidase-4 (DPP-4) degradation.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.